Tepmetko (tepotinib tablets) — Cigna
Non-Small Cell Lung Cancer (advanced or metastatic, MET exon 14 skipping mutation or high-level MET amplification)
Initial criteria
- Patient age ≥ 18 years; AND
- Diagnosis of advanced or metastatic non-small cell lung cancer; AND
- ONE of the following:
- • Patient has mesenchymal epithelial transition (MET) exon 14 skipping mutation as detected by an approved test; OR
- • Patient has high-level MET amplification as detected by an approved test.
Approval duration
1 year